RPT-193 is under clinical development by RAPT Therapeutics and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RPT-193’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RPT-193 overview

RPT-193 (FLX-193) is under development for the treatment of allergic disorders including atopic dermatitis (eczema), asthma, chronic urticaria (skin rash), allergic conjunctivitis, chronic rhinosinusitis and eosinophilic esophagitis. The drug candidate is administered orally. It acts by targeting chemokine receptor type 4 (CCR4).

RAPT Therapeutics overview

RAPT Therapeutics operates as an immuno-oncology company that discovers and develops novel immuno-oncology agents. The company develops lead oral small molecule compounds such as FLX475 which blocks a receptor called CCR4, found on nearly all human Treg cells that binds to secreted factors made in the tumor microenvironment. It also develops a pipeline of orally-available small-molecule drugs to activate the immune system and eradicate cancer. The company has advanced into the clinic with a dual-inhibitor drug that targets FLT3 and CDK4 and 6 for the treatment of cancer. RAPT Therapeutics is headquartered in South San Francisco, California, the US

For a complete picture of RPT-193’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.